AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialResearch in context

AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialResearch in context

Summary: Background: Inhibiting vascular endothelial growth factor (VEGF) function can improve the efficacy of immunotherapy by modulating the tumor immune microenvironment. AK112 is the first-in-class humanized IgG1 bispecific antibody targeting programmed death-1 (PD-1) and VEGF. This study aimed...

Full description

Bibliographic Details
Main Authors: Yuanyuan Zhao, Gang Chen, Jianhua Chen, Li Zhuang, Yingying Du, Qitao Yu, Wu Zhuang, Yanqiu Zhao, Ming Zhou, Weidong Zhang, Yu Zhang, Yixin Wan, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:EClinicalMedicine
Subjects:
AK112
Bispecific antibody
Non-small cell lung cancer
PD-1
VEGF
Anti-angiogenesis
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023002833

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023002833

Similar Items